Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEPW) Return on Capital Employed (2021 - 2025)

Coeptis Therapeutics Holdings has reported Return on Capital Employed over the past 5 years, most recently at 0.97% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.97% for Q4 2025, down 42.0% from a year ago — trailing twelve months through Dec 2025 was 0.97% (down 42.0% YoY), and the annual figure for FY2025 was 1.21%, down 11.0%.
  • Return on Capital Employed for Q4 2025 was 0.97% at Coeptis Therapeutics Holdings, down from 0.54% in the prior quarter.
  • Over the last five years, Return on Capital Employed for COEPW hit a ceiling of 10.79% in Q1 2024 and a floor of 2.67% in Q4 2023.
  • Median Return on Capital Employed over the past 5 years was 0.54% (2025), compared with a mean of 1.37%.
  • Biggest five-year swings in Return on Capital Employed: surged 844bps in 2023 and later tumbled -1144bps in 2025.
  • Coeptis Therapeutics Holdings' Return on Capital Employed stood at 0.36% in 2021, then skyrocketed by 275bps to 0.63% in 2022, then tumbled by -521bps to 2.67% in 2023, then skyrocketed by 79bps to 0.56% in 2024, then tumbled by -75bps to 0.97% in 2025.
  • The last three reported values for Return on Capital Employed were 0.97% (Q4 2025), 0.54% (Q3 2025), and 0.63% (Q2 2025) per Business Quant data.